CD109 and triple-negative breast carcinoma: CD109 expression was also found to be greater in triple-negative breast cancer (TNBC) compared to non-TNBC and to be associated with higher rate of distant metastasis and worse postoperative disease-specific survival compared to those with low or no expression [31].